Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):823-825.
doi: 10.1016/j.arbres.2020.07.006.
Epub 2020 Aug 13.
[Article in
English,
Spanish]
Affiliations
- 1 Paediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain. Electronic address: claracarrerasabad@gmail.com.
- 2 Paediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
- 3 Department of Paediatric Ophthalmology, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
- 4 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Francie van Zijl Avenue, Clinical Building, K Floor, Tygerberg Campus Stellenbosch University, Cape Town, South Africa.
No abstract available
MeSH terms
-
Antitubercular Agents / adverse effects
-
Diarylquinolines
-
Humans
-
Pharmaceutical Preparations*
-
Tuberculosis, Multidrug-Resistant* / drug therapy
Substances
-
Antitubercular Agents
-
Diarylquinolines
-
Pharmaceutical Preparations